Please login to the form below

Not currently logged in
Email:
Password:

non-Hodgkin's lymphoma

This page shows the latest non-Hodgkin's lymphoma news and features for those working in and with pharma, biotech and healthcare.

Precision BioSciences to raise $100m for off the shelf CAR-Ts

Precision BioSciences to raise $100m for off the shelf CAR-Ts

leukaemia and non-Hodgkin lymphoma (NHL). ... It’s a bold claim, but if the drug operates as claimed, then the company could offset some of the issues associated with first generation CAR-T therapies.

Latest news

  • FDA begins speedy review of Celgene’s Revlimid combo in lymphoma FDA begins speedy review of Celgene’s Revlimid combo in lymphoma

    Known as R. 2. , the combination is being evaluated for those with previously treated follicular and marginal zone lymphoma, and if approved, the therapy could free patients of chemotherapy. ... of non-Hodgkin’s lymphoma), but failed to show any

  • Xencor’s Novartis-partnered bispecific on hold after patient deaths Xencor’s Novartis-partnered bispecific on hold after patient deaths

    It’s not the first CD3-targeting bispecific to run into safety concerns. ... In this case however the concerns were about liver toxicity. A few weeks earlier a trial of Affimed’s CD3- and CD19-targeting bispecific AFM11 in non-Hodgkin’s lymphoma

  • CMS proposes coverage scheme for CAR-T therapies CMS proposes coverage scheme for CAR-T therapies

    Sciences’ Yescarta (axicabtagene ciloleucel) given the nod shortly afterwards for various forms of non-Hodgkin’s lymphoma (NHL) including DLBCL. ... These one-time treatments have shown remarkable results in lymphoma and leukaemia patients who have

  • CAR-Ts take centre stage as ASH18 comes to a close CAR-Ts take centre stage as ASH18 comes to a close

    now been incorporated in a programme in non-Hodgkin’s lymphoma due to start next year. ... Gilead also had new, two-year data to share on its already-marketed CAR-T Yescarta (axicabtagene ciloleucel) in r/r B-cell lymphoma that showed a sustained

  • China’s Innovent to start US trials of anti-CD47 cancer drug China’s Innovent to start US trials of anti-CD47 cancer drug

    Innovent reckons IB-188 has stronger receptor blocking ability than other investigational drugs against CD47, and says it intends to start several clinical trials across multiple cancers, including non-Hodgkin's ... lymphoma and ovarian cancer.

More from news
Approximately 15 fully matching, plus 110 partially matching documents found.

Latest Intelligence

  • Pharma deals during October 2014 Pharma deals during October 2014

    Zykadia is approved in the US for patients with anaplastic lymphoma kinase (ALK) and metastatic NSCLC but not approved elsewhere; INC 280 and EFG 816 are in phase 1 development; the ... Hodgkin's lymphoma.

  • Interview: Kay Drake and Naoki Okamura, Astellas Interview: Kay Drake and Naoki Okamura, Astellas

    The company has also out-licensed a non-small cell lung cancer treatment (Tarceva) and non-Hodgkin's lymphoma treatment (bendamustine) to its strategic partners, with several prospective new oncology medications ... So that's where we need the diversity,

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Therapy Watch expands oncology and IBD portfolios

    Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer

  • Therapy Watch expands its oncology portfolio

    Therapy Watch SCCHN is part of a wider portfolio which covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer (PCa), Renal

  • Oncology drugs under AMNOG

    Pixuvri: Polycomparator segmentation by the G-BA removes statistical power. Cell Therapeutics gained European approval for Pixuvri (pixantrone) in non-Hodgkin’s B-cell lymphoma, on the basis of a trial ... against ‘treatment of physician’s

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics